ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

CROSSTALK to Fight against Inflammation and Fibrosis: New Biological Medical Drugs Design for a New Age |Biomedgrid

Journal: American Journal of Biomedical Science & Research (Vol.16, No. 1)

Publication Date:

Authors : ;

Page : 63-65

Keywords : Commercialization; Immunogenicity reactions; Agonism; Synergy; Antifibrotic action;

Source : Downloadexternal Find it from : Google Scholarexternal


Inflammation is the response of an organism's immune system to damage caused to its cells and vascularized tissues by any type of aggression, which may be of a biological, chemical, or physical nature. This inflammatory response must be self-limiting in time and intensity, since, if this is not the case and there is not perfect coordination between the innate and adaptive immune systems, at the very least a fibrotic process will be generated that will lead to a percentage loss of function in the affected tissue or tissues, and, in severe cases, could lead to a severe systemic inflammatory syndrome with positive feed-back systems, leading to a cytokine storm, which in turn could lead to multi-organ failure [1,2]. In the establishment, maintenance and termination of such a cytokine storm at the molecular level, soluble cytokine-like mediators (especially IL-1, IL-6, IL-18, etc...), growth factors (TNF-α, etc...), chemokines (MCP- 1, MIP-1, etc...), molecules related to the cytokines (MCP-1, MIP- 1, etc...) and cytokine-related molecules (MCP-1, MIP-1, etc...) are essential for the establishment, maintenance and termination of such a cytokine storm. ), molecules related to the purinergic system (ATP, ADP), which will act on receptors such as Toll-like Receptors (TLRs), NOD-like Receptors (NLRs), RIG-type Helicase Receptors (RLRs) and purinergic receptors (P2X7).

Last modified: 2024-02-15 21:59:10